Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|September 5, 2020
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trialNathalie Baize, Isabelle Monnet, Laurent Greillier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2021
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLCRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung CancerJordi Remon, Benjamin Besse, Santiago Ponce Aix, et al.
Molecular Oncology|February 22, 2020
Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survivalLisa Quetel, Clément Meiller, Jean-Baptiste Assié, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 StudyRomain Corre, Laurent Greillier, Hervé Le Caër, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid CarcinomaCharlotte Domblides, Karen Leroy, Isabelle Monnet, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2023
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018Olivier Bylicki, Pascale Tomasini, Gervais Radj, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2022
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohortSimon Baldacci, Benjamin Besse, Virginie Avrillon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE TrialJulien Mazieres, Fabrice Barlesi, Isabelle Rouquette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2020
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 StudyRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.
Pageof 12